

RECEIVED

AUG. 2. 2005 5:44PM

MOFO 28TH FL CENTRAL FAX CENTER

NO. 380 P. 4

AUG 02 2005

Application No.: 09/623,533

2

Docket No.: 500862001520

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application.

Claim 1 (currently amended): ~~An isolated, modified anti-viral peptide consisting of: a peptide that has been modified to contain a succinimide or maleimide containing group which is reactive with amine groups, hydroxyl groups, or thiol groups on blood components~~ cysteine 34 of serum albumin to form a stable covalent bonds, said peptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 534, SEQ ID NO: 535, SEQ ID NO: 536, SEQ ID NO: 537, SEQ ID NO: 538, SEQ ID NO: 539, SEQ ID NO: 540, and SEQ ID NO: 541, said sequence exhibiting an anti-viral activity against human immunodeficiency virus (HIV) wherein said ~~isolated~~ peptide is covalently bonded to ~~a blood component~~ cysteine 34 of serum albumin, wherein the ratio of peptide to serum albumin is 1:1.

**Claim 2 (canceled).**

**Claim 3 (canceled).**

Claim 4 (currently amended): ~~The isolated, modified peptide of claim 1 wherein said peptide is DP 178, the amino acid sequence of which is SEQ ID NO:1.~~

**Claim 5 (canceled).**

Claim 6 (currently amended): ~~The isolated, modified peptide of claim 1 wherein said peptide has an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 534, SEQ ID NO: 535, SEQ ID NO: 536, SEQ ID NO: 537, SEQ ID NO: 538, SEQ ID NO: 539, SEQ ID NO: 540, and SEQ ID NO: 541.~~

**Claims 7-18 (canceled).**

sf-1960951

BEST AVAILABLE COPY

Application No.: 09/623,533

3

Docket No.: 500862001520

BEST AVAILABLE COPY

Claim 19 (currently amended): A composition for use in the prevention and/or treatment of acquired immune deficiency syndrome (AIDS) comprising, in a physiologically acceptable medium, a modified peptide consisting of a peptide that has been modified to contain a succinimidyl or maleimide containing group which is reactive with ~~amino groups, hydroxyl groups, or thiol groups on blood components~~ cysteine 34 of serum albumin to form a stable covalent bonds, said peptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 534, SEQ ID NO: 535, SEQ ID NO: 536, SEQ ID NO: 537, SEQ ID NO: 538, SEQ ID NO: 539, SEQ ID NO: 540, and SEQ ID NO: 541, said sequence exhibiting an anti-viral activity against human immunodeficiency virus (HIV) wherein said peptide is covalently bonded to ~~a blood component~~ cysteine 34 of serum albumin, wherein the ratio of peptide to serum albumin is 1:1.

Claim 20 (previously presented): The composition of claim 19 wherein said succinimidyl or maleimide containing group is a maleimido containing group which is reactive with a thiol group on a blood protein.

Claim 21 (previously presented): The composition of claim 20 wherein said peptide is DP 178, the amino acid sequence of which is SEQ ID NO:1.

**Claims 22-30 (canceled).**

Claim 31 (previously presented): The composition of claim 19 wherein said peptide has an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 534, SEQ ID NO: 535, SEQ ID NO: 536, SEQ ID NO: 537, SEQ ID NO: 538, SEQ ID NO: 539, SEQ ID NO: 540, and SEQ ID NO: 541.

**Claims 32-35 (canceled)**

sf-1960951

Application No.: 09/623,533

4

Docket No.: 500862001520

BEST AVAILABLE COPY

Claim 36 (previously presented): A composition comprising the modified anti-viral peptide of claim 1 in a physiologically acceptable medium.


Claim 37 (canceled).

Claim 38 (previously presented): The composition of claim 36 wherein said modified anti-viral peptide has the amino acid sequence of SEQ ID NO:1.

Claim 39 (previously presented): The composition of claim 36 wherein said modified anti-viral peptide has an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 534, SEQ ID NO: 535, SEQ ID NO: 536, SEQ ID NO: 537, SEQ ID NO: 538, SEQ ID NO: 539, SEQ ID NO: 540, and SEQ ID NO: 541.

Claims 40-51 (Canceled).

Claim 52 (previously presented): The modified anti-viral peptide of claim 1 wherein said peptide has the formula:



((SEQ ID NO:1)-Lys-( $\epsilon$ -MPA)).

sf-1960951


BEST AVAILABLE COPY

Application No.: 09/623,533

5

Docket No.: 500862001520

Claim 53 (previously presented): The composition of claim 19 wherein said peptide has the formula:



((SEQ ID NO:1)-Lys-( $\epsilon$ -MPA)).

Claim 54 (canceled).

Claim 55 (previously presented): The composition of claim 36 wherein said peptide has the formula:



((SEQ ID NO:1)-Lys-( $\epsilon$ -MPA)).

Claims 56-58 (canceled)

sf-1960951

Application No.: 09/623,533

6

Docket No.: 500862001520

Please add the following new claims:

59. (new) The modified peptide of claim 1 wherein said serum albumin is in blood.

60. (new) The modified peptide of claim 59 wherein said peptide is serum albumin blood is in a human.

sf-1960951

BEST AVAILABLE COPY